Roth MKM analyst Jason Wittes initiated coverage of Monogram Orthopaedics (MGRM) with a Buy rating and $4 price target The firm believes Monogram’s mBos robotics platform simplifies surgery with autonomous cutting. It sees the company excelling in bone preparation and personalization, challenging Stryker’s dominance in robotics.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.